You are here

Article Text

Article menu
Download PDFPDF
Editorial
Dabigatran and apolipoprotein B

https://doi.org/10.1136/heartjnl-2015-308575

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests The author is chair of the Netherlands Federation of Anticoagulation clinics and is involved in several experimental and clinical studies with different anticoagulants. However, he does not hold any stock or has any other financial interests in the development, or use of any anticoagulant as antithrombotic or antiatherosclerotic agent.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Cardiac risk factors and prevention
      Dabigatran etexilate and reduction in serum apolipoprotein B
      Philip Joseph Guillaume Pare Lars Wallentin Stuart Connolly Salim Yusuf Jia Wang Michael Ezekowitz John Eikelboom Agneta Siegbahn Paul Reilly Ellison Themeles Jonas Oldgren
      Heart 2015; 102 57-62 Published Online First: 09 Nov 2015. doi: 10.1136/heartjnl-2015-307586
    • Heartbeat
      Heartbeat: Echo anytime, anywhere by anyone?
      Catherine M Otto
      Heart 2015; 102 1-2 Published Online First: 11 Dec 2015. doi: 10.1136/heartjnl-2015-309050